We have constructed a prostate tumor-specific conditionally replicating adenovirus (CRAd), named Ad5PB_RSV-NIS, which expresses the human sodium iodine symporter (NIS) gene. LNCaP tumors were established in nude mice and infected with this CRAd to study tumor viral spread, NIS expression, and efficacy. Using quantitative PCR, we found a linear correlation between the viral dose and viral genome copy numbers recovered after tumor infection. Confocal microscopy showed a linear correlation between adenovirus density and NIS expression. Radioiodide uptake vs virus dose-response curves revealed that the dose response curve was not linear and displayed a lower threshold of detection at 10 7 vp (virus particles) and an upper plateau of uptake at 10 11 vp. The outcome of radiovirotherapy was highly dependent upon viral dose. At 10 10 vp, no significant differences were observed between virotherapy alone or radiovirotherapy. However, when radioiodide therapy was combined with virotherapy at a dose of 10 11 vp, significant improvement in survival was observed, indicating a relationship between viral dose-response uptake and the efficacy of radiovirotherapy. The reasons behind the differences in radioiodide therapy efficacy can be ascribed to more efficient viral tumor spread and a decrease in the rate of radioisotope efflux. Our results have important implications regarding the desirable and undesirable characteristics of vectors for clinical translation of virus-mediated NIS transfer therapy.
INTRODUCTION
Prostate cancer is the second most frequently diagnosed cancer and sixth most frequent cause of cancer death in men worldwide. 1 To date, no uniformly curative therapy for metastatic prostate cancer has been developed. In some malignancies, for which existing treatment regimens are not completely effective, suicide gene therapy and virotherapy strategies targeting the tumorassociated genetic alterations represent rational directions for the development of novel therapeutics. [2] [3] [4] The sodium iodide symporter (NIS) is a transmembrane glycoprotein that mediates uptake of iodide into cells, especially thyroid follicular cells. 5, 6 The presence of NIS on the basolateral membrane of thyroid cells has been exploited for many years for diagnostic imaging purposes as well as for ablative therapy of benign thyroid disease and differentiated thyroid cancer using radioactive iodide ( 131 I). This non-invasive therapy has proven to be a safe and effective treatment for thyroid cancer, even in advanced, metastatic disease. 7, 8 In order to extend the use of NISmediated radioiodide therapy to other types of cancer, we have successfully transferred and expressed the NIS gene in prostate, 9 colon, 10 and breast cancer cells, 11 both in vivo and in vitro, using adenoviral vectors. Our experience with adenovirus-mediated NIS transfer and radioiodide therapy was confirmed in large animal model and has culminated in the opening of a phase I trial for prostate cancer that is currently accruing patients. 12, 13 In addition to its therapeutic potential, NIS transfer allows for non-invasive imaging. NIS-mediated imaging has been used to: confirm viral infection and NIS gene expression and function, 14 quantitate intratumoral (IT) radioisotope uptake in vivo, 15 monitor ectopic expression of the NIS gene in vivo in biodistribution studies, 16 and to determine optimal therapeutic 131 I delivery timing. 9 Groot-Wassink et al. 17 correlated NIS-mediated radioiodide uptake to viral-injected doses and NIS mRNA expression by imaging. Although a linear correlation between positron emission tomography scanning and postmortem g counts in healthy liver was found, the correlation between viral dose (and NIS mRNA) to radioiodide uptake was non-linear. Thus, the relationship between NIS-mediated radioiodide uptake and the viral dose injected in tumors is unclear. In addition, a clear relationship between radioiodide uptake and efficacy has not yet been established.
We have developed a prostate-specific, conditionally replicating adenoviral vector that also harbors the NIS gene. 9 In this conditionally replicating adenovirus (CRAd) Ad5PB_RSV-NIS, the transcriptional control of the E1A gene is governed by a composite probasin promoter targeting prostate cells in order to reduce extratumoral toxicity by induction of tumor selective replication and cell lysis. NIS expression allows for non-invasive imaging and reporting as well as the potential for radioiodidemediated therapy. This combination of virus-mediated oncolysis and NIS-mediated radioiodide therapy has been termed by Dingli et al. 18 as 'Radiovirotherapy'. In this report, we have used a xenograft model using LNCaP cells in nude mice which are transduced in vivo with the 1 Ad5PB_RSV-NIS CRAd. Confocal microscopy and SPECT/CT (singlephoton emission computed tomography/computed tomography) NIS imaging were used to analyze tumor viral spread. We have also established radioiodide uptake vs viral dose-response curves and have correlated our imaging studies to radiovirotherapy treatment efficacy. The results show that the outcome of radiovirotherapy is greatly dependent upon viral spread within the tumor. Moreover, we show that the radioiodide uptake vs viral dose-response curve is complex, steep, and limited by a lower and an upper plateau of uptake. We also present evidence indicating that the upper imaging threshold further defines a minimal viral dose for effective radiovirotherapy. We have found that radioiodide efflux and viral spread are the major components in the treatment outcome. We discuss how our results impact upon the clinical translation of virus-mediated NIS transfer therapy.
RESULTS

Correlation between injected and viral dose delivered in IT injection
In order to measure the number of viral genome copies that are actually present within the tumor after IT injection, we performed quantitative PCR assays of tumor samples after virus injection. LNCaP xenograft tumors established in nude mice were infected with a single dose of Ad5PB_RSV-NIS at 10 7 , 10 9 , or 10 11 vp (virus particles). Three days post-injection, animals were killed and the tumors were tested for viral genome copy contents. Each tumor was assayed in triplicate. Figure 1 shows a linear correlation between the viral dose injected and the numbers of viral genome copies recovered. Thus, at a dose of 10 11 vp, 1.88 Â 10 7 genome copies per mg of tumor were recovered. Because the ratio of vp to pfu (plaque-forming units) in our preparation is 100:1, this result indicated that approximately 1 in 50 pfu of injected virus was detectable in the tumor at day 3.
Correlation between viral presence and NIS expression We delivered the Ad5PB_RSV-NIS CRAd IT to four different mice at a dose of 10 11 vp. On days 3 and 10, two mice were killed and their tumors removed and frozen after immersion in OCT (optimal cutting temperature). Four mm-thick slide sections obtained from the tumors were stained for Ad5 hexon (fluorescein isothiocyanate (FITC)) and NIS (Texas Red). Uninfected tumors were also processed similarly and used as controls. At least 25 photographs spanning the whole slides were taken from each tumor. No signal was detected in the control tumors (Figure 2a ). Clear Ad5 foci can be seen on infected tumors both at days 3 ( Figure 2b ) and 10 (not shown), indicating persistence of virus infection. The virus was spread throughout the tumor as it was found in 80 out of 82 (98%) of the images analyzed. NIS expression was restricted to areas of virus infection (Figure 2b ). Both hexon and NIS signal were quantitated by counting the intensity of green and red pixels in each slide. The values obtained for days 3 and 10 were plotted against each other (Figures 2c and d) . A linear correlation between green pixels (hexon) and red pixels (NIS) was found that was virtually identical between the two time points (r 2 ¼ 0.73, slope ¼ 1.23). These data indicate that NIS expression was proportional to the virus load within the tumor and this correlation was independent of time. Figure 3a shows uptake of the radiotracer in the stomach and the thyroid due to native NIS expression as well as in the bladder as a result of tracer clearance in the urine. 19 Figure 3a also shows that virus-mediated NIS expression resulted in tumor uptake of 99 Tc and that the strength of the signal increased with viral dose. To further ascertain the nature of NIS expression as a function of the viral dose, we quantified the levels of 99 Tc uptake as a function of the concentration of virus delivered into the tumor. At days 1, 2, and 3 post-injection, three mice per dose were analyzed. At each time point, 0.5 mCi 99 Tc was administered intraperitoneally (i.p.), and the uptake was visualized and quantified by micro-SPECT-CT imaging. The results are shown in Figure 3b . For each dose, uptake remained fairly constant throughout the duration of the study except for the 10 10 vp dose in which a small linear increase was detected. Although at all doses tested we observed that NIS expression mediated 99 Tc uptake above that seen in the uninfected control, surprisingly the level of uptake varied only very slightly between the doses of 10 7 and 10 10 vp, then increased threefold at 10 11 vp. The day-3 dose response curve was plotted and demonstrated a steep increase in radiotracer uptake between the doses of 10 9 and 10 11 vp (Figure 4a ). Because we showed in Figure 1a linear relationship between dose injected and the number of viral genome copies, we plotted the dose response curve as a function of genome copies per mg of tumor. This curve was plotted and fitted for viral doses between 10 7 and 10 11 vp. For the dose interval analyzed, the dose response curve could only be fitted by a very steep logistic function as shown in Figure 4b . This result indicated that measurable NIS-mediated uptake has a lower threshold of detection at approximately 10 7 vp and an upper plateau of uptake at 10 11 vp.
Correlation between viral dose response and efficacy We have shown previously with this vector that the combination of radiotherapy and cytolytic virotherapy was superior to virotherapy alone. 9 In light of the finding of a very steep virus dose response with a lower threshold and an upper plateau, we wished to determine the effect of this phenomenon on the efficacy of radiovirotherapy. To address this question, LNCaP xenografts were established in seven groups of mice (average group size n ¼ 10±3). One group of mice was used as control (C), four groups received a single IT dose of Ad5PB_RSV-NIS at 10 9 , 10 10 , or 10 11 vp each (virotherapy V), and the following four groups received each a single IT injection of Ad5PB_RSV-NIS at the aforementioned vp doses, and 4 days later, a single i.p. dose of 3 mCi 131 I. The survival of each group was determined using Kaplan-Meier curves ( Figure 5 ). The survival times were subjected to a Cox proportional hazards survival regression model ( Figure 5 ). Treatment of tumors with Ad5PB_RSV-NIS at a dose of 10 9 vp resulted in no significant difference compared with the untreated control cohort. A modest improvement in the outcome was observed when radioiodide was also administered, but this difference was not statistically significant when compared with the control group. A therapeutic effect was observed at a viral dose of 10 10 vp. However, at this viral dose, radioiodide treatment did not improve efficacy of the treatment. Compared with 10 10 vp plus or minus radioiodide, no significant differences were observed at a dose of 10 11 vp. However, when radioiodide therapy was combined with virotherapy at a dose of 10 11 vp, a major improvement on the outcome of the treatment was observed ( Figure 5 ). Thus, the observed radioiodide viral doseresponse uptake ( Figure 4 ) correlated with the efficacy of radiovirotherapy.
Pinhole imaging and radioisotope efflux We hypothesized that the differences in radioiodide therapy efficacy observed between the doses of 10 10 and 10 11 vp may be due to improved viral spread and dispersion. As indicated above, using confocal microscopy, we observed that upon delivering a dose of 10 11 vp, the virus was better dispersed throughout the tumor. We examined this further using pinhole micro-SPECT/CT to compare in vivo virus distribution as reported by radionuclide uptake between a dose of 10 10 and 10 11 vp. This technique has been previously shown to accurately resolve viral IT dispersion patterns. 20 LNCaP xenografts were established in the flanks of nude mice. When the xenografted tumors reached approximately 200 mm 3 , a single dose of Ad5PB_RSV-NIS at 10 10 or 10 11 vp was administered IT and NIS-mediated 99 Tc uptake was visualized. Figure 6a shows that at 10 10 vp discrete foci of virus infection were formed within the tumor leaving large areas of tissue where no detectable viral signal was detected. On the other hand, the pinhole imaging at 10 11 vp indicated that the virus was evenly distributed throughout the tumor (Figure 6b ). Thus, this data indicates that the difference in radiovirotherapy between the 10 10 vp dose and the 10 11 vp dose may reside in a better viral dispersion at higher viral doses.
In addition, we determined the amount of remaining 99 mTcpertechnetate in the tumor of mice injected IT with 10 10 or 10 11 vp as a function of time (Figure 6c ). When tumors were infected with Ad5PB_RSV-NIS at 10 11 vp tracer efflux kinetics yielded a t 1/2 of 6.8 h, whereras at 10 10 vp the t 1/2 was 3.9 h. Moreover, comparison of the area under the curve between the two doses indicated that the amount of radioisotope retained was 3 times higher in tumors receiving 10 11 vp compared with those receiving 10 10 vp.
DISCUSSION
We have reported the use of prostate-targeted CRAds expressing the NIS protein in in vivo mouse models of prostate cancer. We have shown in this report that measurable NIS-mediated radioisotope uptake has a lower threshold of detection at 10 7 vp and an upper plateau of uptake at 10 11 vp that correspond to 1.88 Â 10 7 genome copies per mg of tumor, with a very steep viral dose-response curve. The observed radioiodide viral doseresponse uptake correlates well with radiovirotherapy efficacy. Thus, we showed that radioiodide therapy is only effective when approximately 10 7 genome copies per mg of tumor were present within the tumor. At these higher doses, the virus was also dispersed more homogeneously within the tumor. NIS expression was linearly correlated to hexon expression with a Hexon:NIS ratio of B1.2, indicating that almost all infected tumor cells expressed NIS.
As shown by the pinhole imaging studies, at an injected dose of 10 11 vp, robust NIS expression covering the entire tumor was observed. By contrast, at lower viral doses effective NIS expression was limited to discrete foci within the tumors. It is likely that, at these low viral doses, tumor cell killing would be restricted to isolated regions within the tumor, whereas at higher doses, the killing would be extended to larger areas of the tumor. NIS can mediate robust bystander effects through 131 I decay b particle emission that can kill cells within a 2-mm radius. 21 By homogeneously spreading the virus throughout the tumor, a more effective bystander effect is likely. Our confocal microscopy results showed that although the virus was distributed over the entire tumor, not all cells were infected with Ad5PB_RSV-NIS. However, homogeneous viral distribution will result in overlapping 'killing zones', resulting in larger areas of destruction of the tumor mass.
A second consequence of a better viral dispersion and NIS expression is an increase in the t 1/2 of radionuclide efflux. The t 1/2 parameters are dependent on the values of clearance and volume of distribution 22 and increased t 1/2 translates into a better Tc uptake was visualized using non-invasive micro-SPECT-CT imaging system. (a) Quantification of 99 Tc tumor uptake at the indicated dose was done using the PMOD Biomedical Image Quantification and Kinetic Modeling Software (PMOD Technologies). (b) Viral dose was transformed to viral genomes per mg of tumor using the equation fitting the curve depicted in figure1. The resulting curve was fitted using a logistic model. retention time of the radioisotope within the tumor. Because the functional parameters of NIS are not likely dependent upon the concentration of the protein achieved by expression, we did not expect the tracer efflux t 1/2 to vary so widely between doses. The likely explanation for this variation in t 1/2 values is that the radionuclide is more readily re-uptaken by neighboring cells after efflux when NIS expression is more robust at 1.88 Â 10 7 genome copies per mg of tumor. The area under the curve between the two doses also indicates that the amount of radioisotope retained was three times higher in tumors receiving 10 11 vp compared with those receiving 10 10 vp, explaining the large difference in therapeutic outcome between the two doses. This phenomenon was previously implied from the decrease in the slopes of efflux curves as the number of cells expressing NIS increased. 23 Our results demonstrate this same effect in vivo. At 10 11 vp, more cells are infected and the expression is more diffuse, thus more overall cells express NIS, than at 10 10 vp. The slopes of the efflux curves are 0.101 and 0.175, respectively at these two doses. Thus, our results agree with those of Dingli et al., while at the same time give a biological and therapeutic importance to the previously observed pharmacokinetic parameters. Higher NIS expression results in slower efflux of radionuclide from the tumor.
One of the major problems that needs to be circumvented for effective cancer gene therapy to be translated into the clinical setting is the limited ability to efficiently transduce tumors with effective levels of therapeutic transgenes. 24, 25 The data presented here corroborate this issue. But our findings also address a recent report from a clinical trials of a NIS-expressing adenovirus that produced poor results with respect to uptake of radioiodide. 26 Barton et al. observed that the mean absorbed dose from administration of their vector into recurrent prostate cancers was well below the dose needed for a favorable therapeutic outcome. On the basis of our current results, it can be argued that to be successful, a NIS-expressing virus needs to be efficiently spread within the tumor and NIS robustly expressed in order to reach the upper threshold and achieve more effective uptake.
A major limitation to viral spread is the high interstitial fluid pressure in solid tumors. 27 This limitation may be overcome by improving either the method of viral infusion or by improving the replicating capabilities of the virus 28 or both. Until better methods of virus delivery are developed, virus replicating capabilities and/ or virus targeting will be the limiting factor(s) to viral spread. 29, 30 Thus, a rational approach should be undertaken in the design of viral vectors to improve these factors. In addition, for viruses destined to treat metastatic disease, modifications that alter liver tropism must also be an important consideration. For example, adenoviruses that contain modifications of important genes involved in replication, such as Ad-ONYX-015, 31, 32 should be avoided in favor of transcriptional-dependent regulation because modifications of replication controlling genes can result in significant virus attenuation that seem unlikely to meet clinical needs. 33 In addition, viral genes, such as the E3 adenoviral death protein gene, that have a role in adenoviral dispersal may be retained where possible to enhance viral spread. 34 Placing the NIS gene under the control of a potent promoter, as in our current construct, also results in stronger NIS expression. Finally, research on novel adenovirus serotypes and/or shielded viral capsid is also important as is that of serotypes that either de-targets the virus from liver sequestration and/or have low seroprevalance, thus reducing the effects of pre-existing immunity. [35] [36] [37] In conclusion, we present data that corroborates the efficacy of radiovirotherapy of non-thyroid malignancies. Our results, however, point out to the need for well-designed vectors capable of efficiently spreading within the tumor and resulting in robust NIS expression.
MATERIALS AND METHODS
CRAd construction
The structure Ad5PB_RSV-NIS CRAd is as described elsewhere. 9 
Cell culture
The androgen-dependent (LNCaP), prostate cancer cell line was cultured as described. 38 
Animal experiments
Experimental protocols were approved by the Mayo Foundation Institutional Animal Care and Use Committee. All animals were purchased from Harlan Laboratories (Indianapolis, IN, USA) and maintained in the Mayo Foundation animal barrier facilities.
Subcutaneous tumor model
Xenografts derived from the LNCaP cell line were established into the right flanks of 4-6-week-old athymic nude Foxn1nu mice (Harlan Laboratories) by subcutaneous injection of 4 Â 10 6 cells resuspended in 0.125 ml media and 0.125 ml of BD Matrigel basement membrane matrix (BD Biosciences, Bedford, MA, USA). Mice were maintained on a low iodine diet and T4 supplementation (5 mg l À 1 ) in their drinking water throughout the duration of the experimentation to maximize radioisotope uptake in the tumor and reduce uptake by the thyroid. The mice were examined daily for tumor development.
Viral injection
The virus was diluted in saline to the appropriate vp concentration. The volume of injection was 100 ml. Aliquots of the viral solution were deposited in three tumor regions. No pressure was applied for the injection other than normal thumb pressure. at 10 7 , 10 9 , or 10 11 vp. Three days post-infection, mice were killed and the tumors harvested. Three tumor samples weighing 30 mg each were taken from each tumor in each injection group, and DNA was extracted using the DNEasy tissue kit (Qiagen, Valencia, CA, USA) with overnight lysis of tumor tissue in ATL buffer/Proteinase K. Each sample was assayed for Ad5PB_RSV-NIS genome copies using the Applied Biosystems TaqMan Universal PCR System according to the manufacturer's protocol (Applied Biosystems, Foster City, CA, USA). Briefly, reactions contained 300 nM of a forward primer GACGGCTACGACTGAATG from nt27837 to nt27854 in the Ad5 genome, 300 nM of a reverse primer complementing RSV sequences 118 bp upstream of the RSV promoter, CCGCTTTTCGCCTAAACACAC, and 250 nM of a TaqMan probe binding to the forward strand of the junction between Ad5 E3 sequences and the RSV sequences, 6
0 FAM -ATATCTGGCCCGTACATCG CAGAT -Iowa Black FQ, (Integrated DNA Technologies, Coralville, IA, USA). In all, 5 ml of template DNA was amplified in 25 ml reactions using ABI Prism 7900HT Real Time PCR System (Applied Biosystems). Genome copies per milligram of tissue were quantitated using a standard curve generated by amplification of known quantities of viral genomes.
Confocal microscopy
A total of four mice were subcutaneously engrafted with LNCaP as described previously. Mice received a single IT dose of Ad5PB_RSV-NIS at 10 11 vp. At days 3 and 10, two mice were killed and the tumors removed. Control mice were injected with saline. All tumors were immersed in OCT compound, frozen, and sectioned to 4 mm.
Mounted sections were selected from random locations spanning the whole tumor. Immunofluorescence staining was performed as previously described with some modifications. 39 Briefly, sections were fixed in 3% formalin and permeabilized with a 0.5% Saponin solution (phosphatebuffered saline, 50 mg ml À 1 normal mouse serum, and 0.5% Saponin) for 10 min on ice. Before human NIS antibody (mouse IgG 1:2000 dilution) treatment, slides were fixed and then blocked with 10% mouse serum. After washing with phosphate-buffered saline, slides were re-blocked with 10% donkey serum and NIS expression was revealed with a Texas redconjugated donkey Anti-mouse IgG (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Sections were washed five times and blocked with 5% normal goat serum. Adenovirus hexon protein was stained with a goat polyclonal Adenovirus hexon protein conjugated with FITC (1:100; Abcam Inc., Cambridge, MA, USA). Sections were washed with phosphate-buffered saline four times and 100 ml of VECTASHIELD HardSet Mounting Medium with DAPI (4',6-diamidino-2-phenylindole; Vector Laboratories, Burlingame, CA, USA) was added as a counterstain and antifade agent. Texas red/FITCstained cells were analyzed on an LSM 510 confocal laser scanning microscope (Carl Zeiss, Inc., Thornwood, NY, USA). Texas red was excited with a 543 nm helium/neon laser. Emission for Texas red was selected with a 560-615 nm band-pass filter. FITC was excited at 488 nm using an argon laser. Emission for FITC was selected with a 505-550 nm band-pass filter. DAPI was excited at 364 nm using an argon laser. Emission for DAPI was captured through a 385-470 nm band-pass filter. Images were collected at 512 Â 512 pixels resolution using a Â 40 C-apochromat water immersion lens (1.2 n.a.) (Carl Zeiss, Inc.). Four stained sections from each of the time points listed above were analyzed by acquiring at least 25 images in each of the tumor slices. Adobe Photoshop CS5 digital imaging software (Adobe Systems Incorporated, San Jose, CA, USA) was used to quantify the density of red pixels (human NIS) and green pixels (adenovirus hexon protein) in each individual image as described. Non-invasive imaging of xenografted tumors: parallel hole and pinhole When engrafted LNCaP tumor size reached 200 mm 3 , mice were randomly selected for each of the four viral dosing groups (n ¼ 3) and given one IT injection of Ad5PB_RSV-NIS CRAd at 10 7 , 10 9 , 10 10 , or 10 11 vp, respectively. Two mice were injected with saline as a control group. In vivo micro-SPECT-CT imaging was performed 1 h after i.p. injection of 0.5 mCi of 99 Tc. Animals were anesthetized using a Summit Medical Anesthesia Machine (Summit Medical Equipment Company, Bend, OR, USA). Oxygen (2 LPM) was used throughout induction and exam. Induction was performed with 4% isoflurane using an induction chamber. Mice were kept anesthetized throughout the full measurement by 2% isoflurane using a nose cone. Images were acquired using a Gamma Medica XSPECT system (Gamma Medica, Inc., Northridge, CA, USA). The SPECT scan was performed with a low-energy, high-resolution parallel-hole collimator and a single bore, lowenergy, 1 mm aperture pinhole collimator. For the parallel-hole scans, a field of view of 12.5 cm, with a reported resolution of 1-2 mm was used. Sixty four projections, 10 sec/projection, were acquired with a total acquisition time of 13:46 min. For pinhole imaging, the radius of rotation was 5 cm giving a 6.84-cm field of view. Sixty four projections were acquired at 15 sec/projection using a 20% energy window with a total acquisition time of 19:09 min. The CT Scan was performed with a continuous circular orbit of 256. Images were acquired at 80 kVp and 0.28 mA with a slice thickness of 50 mm and a reported resolution of 43 mm. Images were analyzed using the PMOD Biomedical Image Quantification and Kinetic Modeling Software (PMOD Technologies, Zurich, Switzerland). The level of 99 Tc uptake by the tumor was expressed as tumor activity in mCi/tumor volume (cc).
Efficacy studies
Mice engrafted with LNCaP as above were divided in groups randomly (average group size n ¼ 10 ± 3). The average tumor size at time 0 was 125 ± 30 mm 
Radioisotope efflux studies
LNCaP xenograft bearing mice were divided into two groups randomly (average group size n ¼ 3). One group of mice received a single IT dose of Ad5PB_RSV-NIS at 10 10 vp; the second group received a dose of 10 11 vp. Three days post infection, a single i.p. dose of 0.5 mCi of 99 Tc was administered. At time intervals, mice were imaged and the images quantified as described above.
Statistics
All curve fittings were performed with SigmaPlot 10.0 (SigmaPlot Software, San Jose, CA, USA). Survival was determined using Kaplan-Meier curves. The survival times were subjected to a Cox proportional hazards survival regression model.
